BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Sells $106,512.90 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Hannah Valantine sold 2,418 shares of the company's stock in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $44.05, for a total value of $106,512.90. Following the completion of the sale, the director directly owned 7,465 shares in the company, valued at approximately $328,833.25. The trade was a 24.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Hannah Valantine also recently made the following trade(s):

• On Thursday, June 26th, Hannah Valantine sold 2,289 shares of BridgeBio Pharma stock. The stock was sold at an average price of $44.05, for a total value of $100,830.45.
• On Tuesday, June 10th, Hannah Valantine sold 4,292 shares of BridgeBio Pharma stock. The shares were sold at an average price of $40.00, for a total transaction of $171,680.00.

BridgeBio Pharma Price Performance

BBIO stock traded up $0.05 during trading on Wednesday, reaching $42.83. 2,641,698 shares of the stock traded hands, compared to its average volume of 2,496,365. The firm has a market capitalization of $8.13 billion, a PE ratio of -12.13 and a beta of 1.15. The business's 50 day moving average price is $37.48 and its 200-day moving average price is $34.36. BridgeBio Pharma, Inc. has a 52-week low of $21.72 and a 52-week high of $45.48.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.12. The firm had revenue of $36.74 million during the quarter, compared to analyst estimates of $57.14 million. During the same period in the prior year, the firm earned ($0.20) earnings per share. The business's revenue for the quarter was down 44.8% on a year-over-year basis. On average, equities research analysts predict that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Analysts Set New Price Targets

BBIO has been the subject of a number of analyst reports. Piper Sandler boosted their price objective on shares of BridgeBio Pharma from $46.00 to $63.00 and gave the company an "overweight" rating in a research report on Wednesday, April 30th. Redburn Atlantic initiated coverage on shares of BridgeBio Pharma in a research note on Monday, March 31st. They issued a "buy" rating and a $50.00 target price for the company. HC Wainwright boosted their price target on BridgeBio Pharma from $53.00 to $56.00 and gave the company a "buy" rating in a report on Monday, June 9th. Wells Fargo & Company raised their price objective on BridgeBio Pharma from $67.00 to $76.00 and gave the stock an "overweight" rating in a report on Monday. Finally, Wall Street Zen raised BridgeBio Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $58.85.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Ironwood Investment Management LLC increased its position in shares of BridgeBio Pharma by 0.5% in the fourth quarter. Ironwood Investment Management LLC now owns 63,157 shares of the company's stock worth $1,733,000 after acquiring an additional 338 shares in the last quarter. GAMMA Investing LLC boosted its position in BridgeBio Pharma by 71.0% during the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company's stock worth $32,000 after purchasing an additional 382 shares during the period. Xponance Inc. increased its holdings in BridgeBio Pharma by 3.8% in the 1st quarter. Xponance Inc. now owns 10,474 shares of the company's stock valued at $362,000 after purchasing an additional 385 shares in the last quarter. Summit Investment Advisors Inc. raised its position in BridgeBio Pharma by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,706 shares of the company's stock valued at $404,000 after purchasing an additional 466 shares during the period. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after purchasing an additional 472 shares in the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.